Barinthus Biotherapeutics
20400 Century Blvd
Germantown
Maryland
United States
Tel: +441865591439
Website: https://www.barinthusbio.com/careers/
Email: recruitment@barinthusbio.com
About Barinthus Biotherapeutics
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. The company stands apart through its broad pipeline, built around four proprietary platform technologies;ChAdOx, MVA, SNAP-TI and SNAP-CI. These platforms are enabling the company to develop antigen-specific immunotherapeutics that aim to optimize the disease-fighting capabilities of T cells and guide them towards a healthy balance. Leading the way with a passion for science embodies everything we do at Barinthus Biotherapeutics – even our new name. Barinthus was the name of the mythological navigator who guided the legendary King Arthur of Britain by ship to the island of Avalon to be healed after he was wounded. Like Barinthus, our company aims to be a strong and resilient guide, navigating those that rely on us toward better health. In this most important journey, our vessel is the power of science and our expertise to harness it in directing the immune system to help people overcome chronic infectious diseases, autoimmunity, and cancer. While our eyes are keenly focused on moving science forward, we also draw inspiration from the past. Aligning the name of our company with an Arthurian legend is a nod to our rich UK-based history as a dedicated steward of science and unwavering champion of patients. If the past is prologue for the future, then we proudly embrace the values and technological approach that continue to be the hallmark and fabric of our company – now more than ever as we blaze on as Barinthus Biotherapeutics.
80 articles about Barinthus Biotherapeutics
-
Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines
12/14/2021
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines, today announced that it has acquired US-based Avidea Technologies, Inc. (“Avidea”).
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV
12/7/2021
Vaccitech plc today announced a promising interim analysis of safety and efficacy data from the HBV002 study, including a review of surface antigen (HBsAg) levels in CHB patients.
-
Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference
11/24/2021
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that Bill Enright, Chief Executive Officer, and Georgy Egorov, Chief Financial Officer, are participating at the 33rd Annual Virtual Piper Sandler Healthcare Conference November 30th to December 2nd, 2021.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses
11/12/2021
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced results from ongoing Phase 1 and Phase 1b/2a clinical trials of VTP-300, an immunotherapy candidate in development for the treatment of CHB infection.
-
Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
11/12/2021
Vaccitech plc announced its financial results for the third quarter, ended September 30, 2021, and provided an overview of the Company’s recent corporate developments.
-
Vaccitech to Present at the Jefferies London Healthcare Conference
11/10/2021
Vaccitech plc, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, announced that Bill Enright, Chief Executive Officer, will be presenting at the Jefferies London Healthcare Conference.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus
11/4/2021
Vaccitech plc, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, announced the publication in The Lancet Microbe of the first Phase 1 clinical trial conducted in the Middle East evaluating the safety and tolerability of the ChAdOx1 MERS vaccine candidate.
-
Vaccitech to Present at Upcoming September Investor conferences
9/9/2021
Vaccitech plc today announced that Bill Enright, Chief Executive Officer, will be presenting at the following investment conferences in September. Event: Morgan Stanley Healthcare Conference 2021
-
Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity.
-
Vaccitech to Present at the William Blair Biotech Focus Conference 2021
7/8/2021
Vaccitech plc today announced that the Company’s Chief Executive Officer, Bill Enright, will be presenting at the William Blair Biotech Focus Conference 2021 on Thursday, July 15 at 1 p.m. EDT.
-
Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
7/6/2021
Arbutus Biopharma Corporation and Vaccitech plc announced that the companies have entered into a clinical trial collaboration agreement to evaluate an innovative therapeutic combination for the treatment of subjects with chronic hepatitis B virus infection who are already receiving standard-of-care nucleoside reverse transcriptase inhibitor therapy.
-
Vaccitech to Present at the Jefferies Virtual Healthcare Conference
6/1/2021
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced that the Company’s Chief Executive Officer, Bill Enright, will be presenting at the Jefferies Virtual Healthcare Conference on Thursday, June 3 at 11:00 AM EDT.
-
Money on the Move: April 29 – May 4
5/5/2021
April showers bring May dollars. Here's whose cash gardens are really blooming this week in the life sciences world. -
Vaccitech Announces Closing of $110.5 Million Initial Public Offering
5/4/2021
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the closing of its initial public offering in the United States of 6,500,000 American Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS.
-
After quietly filing plans for an initial public offering earlier this month, U.K.-based Vaccitech raised $110.5 million in its IPO.
-
Vaccitech Announces Pricing of Initial Public Offering
4/29/2021
Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the pricing of its initial public offering in the United States of 6,500,000 American Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS
-
At this time Vaccitech hasn’t priced its offering, although the report suggests they might sometime this month.